Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | TACR2 | P21452 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SHBG | P04278 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL243359 | 1.00 | HTR1A (0.45) | HTR1AHTR1DHTR1BS1PR1S1PR4 | |
| SCHEMBL1019393 | 1.00 | HTR1A (0.45) | HTR1AHTR1DHTR1BS1PR1S1PR4 | |
| SCHEMBL10999399 | 1.00 | HTR1A (0.45) | HTR1AHTR1DHTR1BS1PR1S1PR4 | |
| SCHEMBL1018863 | 1.00 | HTR1A (0.45) | HTR1AHTR1DHTR1BS1PR1S1PR4 | |
| SCHEMBL11673325 | 1.00 | HTR1A (0.45) | HTR1AHTR1DHTR1BS1PR1S1PR4 | |
| SCHEMBL242143 | 0.98 | HTR1A (0.43) | HTR1AHTR1DHTR1BS1PR1S1PR4 | |
| SCHEMBL242265 | 0.94 | HTR1A (0.41) | HTR1AHTR1DHTR1BS1PR1S1PR4 | |
| SCHEMBL6365081 | 0.92 | HTR1A (0.40) | HTR1AHTR1DHTR1BS1PR1S1PR4 | |
| SCHEMBL28419742 | 0.92 | HTR1A (0.40) | HTR1AHTR1DHTR1BS1PR1S1PR4 | |
| SCHEMBL30387310 | 0.92 | HTR1A (0.40) | HTR1AHTR1DHTR1BS1PR1S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174583-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4347544-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | Dow Technology Investments LLC (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117242047-A | Process for the vapor phase hydrogenation of aldehydes | 陶氏技术投资有限责任公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2022250790-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2022-12-01 | — | — | WO | disclosed |
| EP-2970074-B1 | HYDROFORMYLATION PROVESS USING A HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| CN-104045532-B | Hydroformylation process | 陶氏技术投资有限责任公司 | 2018-05-25 | — | — | CN | disclosed |
| US-9573870-B2 | Hetereocyclic agent as catalytic stabilizing agent in a hydroformylation process | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2017-02-21 | — | — | US | disclosed |
| EP-2970074-A1 | HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT IN A HYDROFORMYLATION PROCESS | Dow Technology Investments LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150376101-A1 | HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT IN A HYDROFORMYLATION PROCESS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY LLC | 2015-12-31 | — | — | US | disclosed |
| CN-105073701-A | Hetereocyclic agent as catalytic stabilizing agent in a hydroformylation process | DOW TECHNOLOGY INVESTMENTS LLC | 2015-11-18 | — | — | CN | disclosed |
| WO-2014149915-A1 | HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT IN A HYDROFORMYLATION PROCESS | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| CN-104045532-A | Hydroformylation process | DOW TECHNOLOGY INVESTMENTS LLC | 2014-09-17 | — | — | CN | disclosed |
| CN-1122655-C | improved metal-ligand complex catalyzed processes | UNION CARBIDE CHEM PLASTIC (US) | 2003-10-01 | — | — | CN | disclosed |
| EP-0873292-B1 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | UNION CARBIDE CHEM PLASTIC (US) | 2001-12-19 | — | — | EP | disclosed |
| CN-1220652-A | improved metal-ligand complex catalyzed processes | UNION CARBIDE CHEM PLASTIC (US) | 1999-06-23 | — | — | CN | disclosed |
| EP-0873292-A1 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1998-10-28 | — | — | EP | disclosed |
| US-5731472-A | HETEROCYCLIC NITROGEN COMPOUNDS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1998-03-24 | — | — | US | disclosed |
| WO-1997020798-A1 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376101-A1 | HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT IN A HYDROFORMYLATION PROCESS | NUDT1, CAT, HRAS | HTR1A 988/4885HTR1D 1323/4885HTR1B 1566/4885 |
| US-20240174583-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | ADH1C, ADH5, ALDH2 | HTR1A 2450/4885HTR1D 1739/4885HTR1B 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.